Background/Objectives: The global incidence of neuroendocrine tumors (NETs) is steadily rising. While modifiable lifestyle factors impact oncological outcomes, the interplay between dietary habits, orthorexia nervosa (ON) tendencies, physical activity levels (PAL), and body image in NET survivors remains poorly understood. Methods: A cross-sectional study was conducted on a convenience sample of 61 patients with NETs. Validated evaluation tools included the PREDIMED questionnaire for Mediterranean Diet (MD) adherence, the GPAQ for PAL, and the ORTO-15 questionnaire for ON risk. Body image satisfaction and comprehensive clinical features were also assessed. Results: Most participants (75.4%) demonstrated moderate MD adherence. Body image dissatisfaction (32.8%) was significantly associated with a higher BMI (28.86 vs. 24.93 kg/m², p < 0.01) and reduced PAL (660.0 vs. 1680.0 MET-min/week, p = 0.021, pFDR = 0.042). Notably, moderate MD adherence was linked to a higher orthorexic risk (corresponding to lower ORTO-15 scores) compared to low adherence (p = 0.032, pFDR = 0.078). Somatostatin analog therapy showed no detrimental impact on behavioral parameters (p > 0.05). Conclusions: These findings highlight specific vulnerabilities in NET patients: body image dissatisfaction correlates with higher BMI and lower physical activity, while moderate Mediterranean Diet adherence associates with orthorexic risk, which is localized and was not independent in multivariate analysis. Targeted nutritional and physical activity interventions should be integrated into multidisciplinary NET care.

Background: Pulmonary neuroendocrine tumors (lung NETs) comprise a biologically heterogeneous group of neoplasms ranging from indolent typical carcinoids to more aggressive atypical carcinoids. Accurate characterization of tumor biology is essential for optimizing staging, prognostic stratification, and treatment selection. Beyond conventional cross-sectional imaging, functional imaging and emerging quantitative imaging techniques are progressively redefining the diagnostic pathway. Methods: We performed a comprehensive narrative review of the current evidence regarding conventional radiological imaging, somatostatin receptor (SSTR) PET/CT, ¹⁸F-FDG PET/CT, dual-tracer imaging, and radiomics in lung NETs, integrating recent international recommendations from ENETS, ESMO, AIOM, and other major societies. Results: Contrast-enhanced CT remains the cornerstone of anatomical staging, whereas ⁶⁸Ga-labelled somatostatin analogue (SSA) PET/CT provides highly sensitive assessment of receptor expression and patient eligibility for somatostatin analogue therapy and peptide receptor radionuclide therapy (PRRT). Conversely, ¹⁸F-FDG PET/CT identifies metabolically active and biologically aggressive disease, particularly in atypical carcinoids and tumors showing dedifferentiation. Increasing evidence supports the complementary role of dual-tracer PET/CT for non-invasive characterization of tumor heterogeneity, prognostic stratification, and treatment planning. Radiomics further expands this paradigm by extracting quantitative imaging biomarkers that may improve histological prediction, recurrence risk assessment, and individualized management. Although promising, radiomics remains limited by methodological heterogeneity and the lack of prospective validation. Conclusions: The integration of conventional imaging, molecular imaging, and quantitative radiomics supports a shift from lesion detection toward biologically driven precision imaging. Future prospective multicenter studies incorporating imaging biomarkers, artificial intelligence, and clinical-pathological variables may further support personalized management of patients with lung NETs.